Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Drug Allergy of HLB3-002 in Healthy Volunteers
NCT06713317Phase 1Completed
- Sponsor
- Huonslab
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hlb3-002 (4 arms), sponsored by Huonslab. Primary endpoint: Incidence rate of drug allergy following intradermal injection of the IP at 2 days. Started Dec 2024; status: completed.
02
Drugs
hlb3-002
Beyond the preview
Go deeper on NCT06713317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713317.